Biology & Ecology
Biology
Gram Statusunknown
Oxygen Toleranceobligate anaerobe
Key Traits
- butyrate-producing
Ecology
Primary Nichesgut
Reservoirhuman
Clinical Profile
Pathobiont
yes
no
context dependent
unknown
Clinical Rolesprotective commensal
Typical Specimenstool
Risk Contextsmelanoma patients receiving immune checkpoint inhibitor therapy (ICB)
Clinical Associations:
E2
E3 — Strong human clinical evidence
E2 — Moderate human evidence
E1 — Limited / preliminary
Faecalibacterium prausnitzii relative abundance was enriched in anti-PD-1 responders versus non-responders in the shotgun metagenomic subset of 111 metastatic melanoma patients (n=71 responders, n=40 non-responders; fig. S2A), providing species-level confirmation of its association with immunotherapy response.
PMID:
34941392
E2
E3 — Strong human clinical evidence
E2 — Moderate human evidence
E1 — Limited / preliminary
Faecalibacterium prausnitzii was significantly enriched in anti-PD-1 responders versus non-responders in metagenomic WGS of fecal samples from 25 metastatic melanoma patients (14R, 11NR), establishing the original species-level human evidence of its enrichment in the gut microbiome of immunotherapy responders (Fig. 2F).
PMID:
29097493
E2
E3 — Strong human clinical evidence
E2 — Moderate human evidence
E1 — Limited / preliminary
Faecalibacterium prausnitzii was among the bacterial species significantly enriched in responders (objective response or stable disease >12 months) to FMT plus pembrolizumab in a Phase 2 trial of 15 PD-1-refractory advanced melanoma patients, confirming prior reports; transkingdom network analysis further identified it as negatively correlated with circulating CXCL8 (IL-8), an immunosuppressive cytokine elevated in non-responders.
PMID:
33542131
E2
E3 — Strong human clinical evidence
E2 — Moderate human evidence
E1 — Limited / preliminary
Antibiotic-induced depletion of Faecalibacterium prausnitzii in one PD-1-refractory melanoma patient undergoing FMT plus pembrolizumab (PT-18-0018) was associated with pronounced disruption of the transplanted microbiome and clinical disease progression; re-transplantation from the same donor restored gut colonization and was followed by renewed disease stabilization.
PMID:
33542131
Last reviewed: 2026-04-03
Evidence Timeline
Related Taxa
Shared Niche = same body site
Shared Risk = same vulnerable population
ⓘ